Aisling Capital Management as of June 30, 2022
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 19 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 39.3 | $55M | 6.1M | 9.08 | |
| Syndax Pharmaceuticals (SNDX) | 14.1 | $20M | 1.0M | 19.24 | |
| Monte Rosa Therapeutics (GLUE) | 10.2 | $14M | 1.5M | 9.67 | |
| Biomea Fusion (BMEA) | 6.8 | $9.6M | 799k | 11.98 | |
| Aclaris Therapeutics (ACRS) | 6.3 | $8.9M | 635k | 13.96 | |
| Nuvation Bio Com Cl A (NUVB) | 5.9 | $8.2M | 2.5M | 3.24 | |
| Verona Pharma Sponsored Ads (VRNA) | 4.0 | $5.6M | 1.3M | 4.19 | |
| Elevation Oncology (ELEV) | 2.8 | $4.0M | 2.8M | 1.40 | |
| Talaris Therapeutics | 2.2 | $3.1M | 683k | 4.51 | |
| Poseida Therapeutics I (PSTX) | 1.9 | $2.7M | 1.0M | 2.58 | |
| Reneo Pharmaceuticals (RPHM) | 1.7 | $2.3M | 886k | 2.65 | |
| Spruce Biosciences (SPRB) | 1.5 | $2.1M | 1.2M | 1.74 | |
| Viracta Therapeutics (VIRX) | 0.8 | $1.1M | 289k | 3.88 | |
| Marker Therapeutics Ord | 0.7 | $1.0M | 3.1M | 0.33 | |
| Avrobio Ord (AVRO) | 0.7 | $929k | 1.0M | 0.92 | |
| Aeglea Biotherapeutics | 0.6 | $854k | 1.7M | 0.51 | |
| Atreca Cl A Com (BCEL) | 0.5 | $694k | 388k | 1.79 | |
| Zosano Pharma Corporation Com New | 0.0 | $24k | 78k | 0.31 | |
| Nabriva Therapeutics SHS | 0.0 | $16k | 90k | 0.18 |
